Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

The proposed merger comes nearly a year after Endo emerged from bankruptcy protection. Endo Inc. has entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that ...

Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

Mallinckrodt and Endo said they will merge through a $6.7 billion cash and stock deal creating a combined company that will be intent on bouncing back from their troubled recent histories ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments. The agreement will give ...

Specialty pharmaceutical companies Endo, Inc. (OTC:ENDPQ) and Mallinckrodt (OTC:MNKTQ) announced Thursday plans to combine in a stock and cash transaction worth $6.7B, creating a public firm ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said. The drugmakers, which both emerged ...